PRELUDE THERAPEUTICS INC Net Change in Cash
PRELUDE THERAPEUTICS INC (PRLD) reported Net Change in Cash of -$8.76 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-11
- PRELUDE THERAPEUTICS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was -$13.50M, a 148.57% decline year-over-year.
- PRELUDE THERAPEUTICS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was $27.80M.
- PRELUDE THERAPEUTICS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was -$584.00K.
- PRELUDE THERAPEUTICS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$12.40M, a 162.63% decline year-over-year.
- PRELUDE THERAPEUTICS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $21.97M.
- PRELUDE THERAPEUTICS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was -$12.82M.
- PRELUDE THERAPEUTICS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$5.31M.
- PRELUDE THERAPEUTICS INC cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$1.22M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$8.76M 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | -$13.50M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $21.97M 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $34.25M 10-Q · filed 2025-11-12 | |||
| 2025-06-30 | $13.28M 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | $27.80M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | -$12.82M 10-K · filed 2026-03-10 | |||
| 2024-09-30 | -$14.16M 10-Q · filed 2025-11-12 | |||
| 2024-06-30 | $2.54M 10-Q · filed 2025-08-14 | |||
| 2024-03-31 | -$584.00K 10-Q · filed 2025-05-06 | |||
| 2023-12-31 | -$5.31M 10-K · filed 2025-03-10 | |||
| 2023-09-30 | -$14.71M 10-Q · filed 2024-11-06 | |||
| 2023-06-30 | -$4.16M 10-Q · filed 2024-08-12 | |||
| 2023-03-31 | -$12.40M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | -$1.22M 10-K · filed 2024-02-15 | |||
| 2022-09-30 | $20.19M 10-Q · filed 2023-11-01 | |||
| 2022-06-30 | $18.88M 10-Q · filed 2023-08-03 | |||
| 2022-03-31 | $19.81M 10-Q · filed 2023-05-08 | |||
| 2021-12-31 | -$182.44M 10-K · filed 2023-03-15 | |||
| 2021-09-30 | -$156.88M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $124.81M 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | $144.68M 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | $199.43M 10-K · filed 2022-03-17 | |||
| 2020-09-30 | $215.91M 10-Q · filed 2021-11-12 | |||
| 2020-06-30 | $10.84M 10-Q · filed 2021-08-12 | |||
| 2020-03-31 | $19.85M 10-Q · filed 2021-05-11 | |||
| 2019-12-31 | $3.28M 10-K · filed 2021-03-16 | |||
| 2019-09-30 | $12.04M 10-Q · filed 2020-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |